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Toshihiro Iwasaku, MD,* Masashi Fukunaga, MD,* Akiyo Eguchi, MD,*
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Takeshi Tsujino, MD,‡ Mitsumasa Ohyanagi, MD,† Tohru Masuyama, MD*
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Objectives This study evaluated the effect of pravastatin pre-treatment on post-procedural index of
microcirculatory resistance (IMR) values that are introduced for assessing the status of the microcir-
culation independently of the epicardial area.
Background Pre-treatment with statins decreased the incidence of cardiac enzyme increase after
ercutaneous coronary intervention (PCI). However, 2 different etiologies, distal embolization of ath-
roma or ischemia caused by side-branch occlusion, cannot be differentiated by measuring cardiac
nzyme levels.
ethods Eighty patients with stable angina were randomly assigned to either pravastatin treatment
20 mg/day, n  40) or no treatment (n  40) 4 weeks before elective PCI. An intracoronary pres-
sure/temperature sensor-tipped guidewire was used. Thermodilution curves were obtained during
maximal hyperemia. The IMR was calculated from the ratio of the mean distal coronary pressure at
maximal hyperemia to the inverse of mean hyperemic transit time. Creatine kinase-myocardial band
and troponin I values were measured at baseline and at 8 and 24 h after PCI.
Results Post-PCI troponin I levels tended to be lower in patients with pravastatin treatment (me-
dian: 0.13 [interquartile range (IQR): 0.10 to 0.31] vs. 0.22 [IQR: 0.10 to 0.74] ng/ml, p  0.1). How-
ever, patients with pravastatin treatment had signiﬁcantly lower IMR than did patients without prav-
astatin treatment (median: 12.6 [IQR: 8.8 to 18.0] vs. 17.6 [IQR: 9.7 to 33.9], p  0.007). Multivariate
analysis revealed that the lack of pravastatin pre-treatment was the only independent predictor of
post-PCI impaired IMR (p  0.03).
Conclusions Post-PCI measurement of the IMR conﬁrmed that pre-treatment with pravastatin was
associated with reduced microvascular dysfunction induced by PCI regardless of side branch occlu-
sions. These data suggest that pre-treatment with statin is desired in patients undergoing elective
PCI. (The Impact of Pravastatin Pretreatment on Periprocedural Microcirculatory Damage After Percu-
taneous Coronary Intervention; UMIN000002885) (J Am Coll Cardiol Intv 2011;4:513–20) © 2011 by
the American College of Cardiology Foundation
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514The 3-hydroxy-3-methylglutaryl coenzyme A reductase in-
hibitors (statins) are widely used to decrease cholesterol
synthesis and are well established to reduce vascular diseases
(1–3). As statins became more widely used in greater
umbers of patients, their effects beyond lipid lowering
egan to emerge. Such pleiotropic effects include improve-
ent of endothelial dysfunction (4), increased nitric oxide
ioavailability, antioxidant effects, anti-inflammatory prop-
rties, and stabilization of atherosclerotic plaques. Several
andomized studies demonstrated that pre-treatment with
tatins reduced the incidence of myocardial infarction after
ercutaneous coronary intervention (PCI) in patients with
table angina pectoris (5,6).
Myocardial necrosis, assessed by cardiac marker elevation,
s relatively frequent after elective PCI, occurring in 10% to
0% of cases (4,7,8). Previous studies have reported that
atients with cardiac marker increase after PCI had higher
ate mortality and more unfavorable event-free survival than
id those patients without cardiac marker increase (9,10).
The mechanisms responsible for
the elevation of cardiac marker
after PCI have been identified as
distal embolization, side branch
occlusion, and prolonged balloon
inflation (4,11,12). However,
these different etiologies cannot be
differentiated by measuring car-
diac marker levels.
Recently, the index of micro-
circulatory resistance (IMR) was
introduced for evaluating the
microvascular function using a
coronary pressure/thermistor-
tipped guidewire independently
of the epicardial area (13). The
MR has been validated in an animal model and tested in
table angina patients (13–15). The advantages of IMR over
urrent methods for assessing the microvascular function are
ts relative ease of performance and interpretation, its
ndependence of the epicardial vessel stenosis, its reproduc-
bility, and its quantitative nature. We conducted a prospec-
ive and randomized study to evaluate the effect of prava-
tatin pre-treatment on post-procedural microvascular
mpairment assessed by post-PCI IMR values and cardiac
arker in elective PCI for patients with stable angina
ectoris.
ethods
Study population and study protocol. This was a random-
ized nonblind, prospective study performed in a single
center. Inclusion criteria were the presence of typical stable
effort angina or a positive stress test, and an indication for
Abbreviations
and Acronyms
CK-MB  creatine kinase-
yocardial band
FR  fractional flow
eserve
MR  index of
icrocirculatory resistance
QR  interquartile range
VUS  intravascular
ltrasound
DL  low-density
ipoprotein
CI  percutaneous
oronary interventionPCI of a single de novo lesion 50% diameter stenosis in anative coronary artery. Exclusion criteria were left ventric-
ular ejection fraction30%, acute coronary syndrome in the
previous month, a history of myocardial infarction in the
target vessel–related territory, a history of coronary artery
bypass grafts, any increase in creatine kinase-myocardial
band (CK-MB) or troponin I above the upper normal limit
at the time of randomization, renal dysfunction with creat-
inine 3 mg/dl, chronic total occlusion, in-stent restenosis,
left main lesion, contraindications to adenosine, and previ-
ous treatment with statins.
Between April 2007 and March 2009, 414 patients
underwent elective PCI for stable angina pectoris. Of those,
166 patients were excluded because of previous or current
treatment with statins; 82 because of in-stent restenosis
lesion; 32 because of a potential difficulty to cross the
pressure wire to the lesion due to small diffusely diseased,
tortuous, occluded, or calcified vessels; 24 because of renal
dysfunction; 21 because of low ejection fraction; 5 because
of previous bypass surgery; and 4 because of previous
myocardial infarction in the target vessel–related territory.
Thus, 80 patients fulfilling the inclusion criteria were
scheduled for elective PCI and were included in the study.
Patients were randomly assigned to pravastatin treatment
(20 mg/day, which is the maximum approved dose in Japan
where the study was performed) starting 30 days before the
planned PCI (pravastatin group) or to no statin treatment
(control group); 40 patients were assigned to the pravastatin
group and 40 patients to the control group. Patients were
randomized independently of their lipid levels. According to
our standard protocol, all patients without contraindications
were pretreated with aspirin (100 mg/day) and ticlopidine
200 mg twice a day or clopidogrel 75 mg/day at least 7 days
before the procedure. Before intervention, all patients re-
ceived 100 international units/kg intravenous bolus of un-
fractionated heparin. Additional heparin boluses were given
to maintain activated clotting time 300 s. All patients
rovided written informed consent, and approval of the
residing ethical committee was obtained.
Coronary physiological measurements and intervention.
PCI was performed in a usual manner using coronary stents.
All coronary physiological assessments and interventions
were performed after intracoronary administration of 0.5
mg isosorbide dinitrate. The fractional flow reserve (FFR)
was measured in each patient before and after PCI, and
IMR was measured after PCI using previously described
principles and methods (13–15). Briefly, an intracoronary
pressure/temperature sensor-tipped wire (Radi PressureWire
Certus, St. Jude Medical, Minneapolis, Minnesota) was ad-
vanced through a 6-F guiding catheter to position the pressure
sensor at a point 5 to 10 mm distal from the distal edge of the
stent. Intravenous adenosine triphosphate (140 g/kg/min)
was administered to induce steady-state maximal hyperemia.
Then, 3 injections of saline (3 ml at room temperature) were
administered to the coronary artery through the guiding
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515catheter at maximal hyperemia. The hyperemic transit time
was measured as the time that elapsed between when
one-half of the saline had been injected (defined as T0, and
determined on the temperature curve from the shaft of the
wire) and when one-half of the saline had passed the sensor.
Simultaneous measurements of mean distal coronary pres-
sure were also made in the maximal hyperemic states. FFR
was measured by dividing the mean distal coronary pressure
by the mean aortic pressure during maximal hyperemia
(16,17). IMR was calculated as mean distal coronary pres-
sure multiplied by the hyperemic mean transit time.
Angiographic analysis. Cineangiograms were analyzed us-
ng a computer-assisted, automated edge-detection algo-
ithm (CMS, Medis Medical Imaging Systems, Raleigh,
orth Carolina) by an independent observer who was
naware of the intravascular ultrasound (IVUS) and physi-
logical measurements using standard qualitative and quan-
itative definitions and measurements. The occurrence of
ngiographic complications during PCI was recorded. An-
iographic complications included major side branch occlu-
ions, abrupt intraprocedural vessel closure, major arterial
issection, thrombus formation, and prolonged slow-no
eflow.
IVUS imaging and analysis. IVUS examinations were at-
empted for all patients before and after PCI after intra-
oronary administration of 0.5 mg isosorbide dinitrate using
commercially available system (Atlantis Pro, Boston Sci-
ntific, Natick, Massachusetts). The 40-MHz IVUS cath-
ter was advanced 10 mm beyond the lesion and an
maging run (using automated transducer pullback at 0.5
m/s) was performed to a point 10 mm proximal to the
esion. Lesion plaque composition was assessed visually at
he minimum lumen cross-sectional area site. Image slices
ith the minimum lumen area and the proximal and distal
eferences were identified and measured. Using planimetry
oftware (Tape Measure, INDEC Systems, Santa Clara, Cal-
fornia), vessel area and lumen area were measured. Plaque area
vessel minus lumen area), plaque burden (plaque area divided
y vessel area), and remodeling index (lesion vessel area divided
y mean reference vessel area) were calculated.
Assessment of cardiac markers. The CK-MB and troponin
levels were systematically measured before intervention, at
to 8 h after the procedure, and at 18 to 24 h after the
rocedure. If cardiac marker levels were elevated, serial
easurements were performed every 6 to 8 h until they
eturned to baseline. All cardiac marker determinations
ere performed in the clinical chemistry laboratory by the
ass-determination methods (normal range 0 to 16 units/l
or CK-MB and 0 to 0.1 ng/ml for troponin I).
Statistics. Continuous variables were reported as mean 
SD or median (interquartile ranges). The unpaired Student
t test was used to test the differences between 2 sets of data
with normal distributions. If normality tests failed, the
Mann-Whitney U test was used. Relationships betweenstudied variables were assessed by linear regression. Cate-
gorical variables were reported as frequencies and compared
using chi-square statistics. Intraobserver variability in IMR
measurements was assessed by calculation of the Pearson
correlation coefficients. Multivariate logistic regression anal-
ysis was performed to determine independent predictors of
impaired IMR after PCI. Univariate analyses were first
conducted to identify potential factors for impaired IMR.
The likelihood-ratio test was used, and the variables with a
p value 0.2 were included in the multivariate model. A
p value 0.05 was considered statistically significant.
Results
Baseline clinical characteristics. Baseline clinical and proce-
dural variables in the pravastatin and control groups are
shown in Tables 1, 2, and 3, respectively. The 2 groups were
similar with regard to age, sex, cardiovascular risk factors,
left ventricular function, and concomitant medical therapies
at the time of randomization. Coronary anatomy, lesion
type, procedural characteristics, use of drug-eluting stents,
and diameter and length of stents were also similar. Proce-
dural success was achieved in all patients of the 2 groups.
There were no in-hospital complications (death or need for
emergent revascularization). Total cholesterol and low-
density lipoprotein cholesterol levels at the time of PCI were
significantly lower in the pravastatin group than in the
control group. There was no incidence of significant in-
crease in serum liver enzymes and/or myopathy in the
pravastatin group.
Table 1. Baseline Clinical Characteristics
Pravastatin
(n  40)
Control
(n  40) p Value
Age, yrs 68 8 68 11 0.8
Male 32 (80) 32 (80) 1.0
Hypertension 28 (70) 22 (55) 0.2
Diabetes mellitus 18 (45) 17 (43) 0.8
Current smoker 11 (28) 14 (35) 0.5
Family history of CAD 12 (30) 9 (23) 0.4
Previous myocardial infarction 5 (13) 4 (10) 0.7
Previous coronary intervention 16 (40) 8 (20) 0.1
Left ventricular ejection fraction, % 60 9 63 7 0.2
Medications
Beta blocker 24 (60) 16 (40) 0.1
ACE inhibitor 7 (18) 3 (8) 0.2
AT II antagonist 19 (48) 25 (63) 0.2
Calcium antagonist 13 (33) 16 (40) 0.5
Nitrates 4 (10) 7 (18) 0.4
Body mass index, kg/m2 24 3 24 2 0.5
Duration of pravastatin treatment, days 35 12 — —
Values are mean SD or n (%).ACE angiotensin-converting enzyme; AT II angiotensin II; CAD coronary artery disease.
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516Procedural, angiographic, and IVUS analysis. Procedural
characteristics, angiographic and IVUS data, and pre-PCI
FFR values were comparable in both groups (Table 4).
Glycoprotein IIb/IIIa inhibitors were not used because they
are not approved in Japan. The incidence of angiographic
complications during the procedure was similar between the
2 groups. The frequency of major side branch occlusions was
5% in the pravastatin group and 8% in the control group
(p  0.9). Major arterial dissection occurred in only 1
patient, who was in the pravastatin group.
Physiological measurements and cardiac markers. After
PCI, physiological parameters were successfully obtained in
all patients. Although FFR values were similar between the
2 groups, IMR values were significantly lower in the
pravastatin group than in the control group (median: 12.6
Table 2. Biomarker Characteristics
Pravastatin
(n  40)
Control
(n  40) p Value
Serum creatinine, mg/dl 0.8 0.1 0.8 0.2 0.4
Lipid proﬁles, mg/dl
At randomization
Total cholesterol 215 25 205 29 0.1
LDL cholesterol 132 19 122 28 0.1
HDL cholesterol 54 16 50 11 0.5
Triglycerides 160 101 143 47 0.2
At the procedure
Total cholesterol 173 22 199 25 0.001
LDL cholesterol 91 17 118 27 0.001
HDL cholesterol 51 12 49 11 0.5
Triglycerides 141 76 138 52 0.5
Values are mean SD.
HDL high-density lipoprotein; LDL low-density lipoprotein.
Table 3. Procedural Characteristics
Pravastatin
(n  40)
Control
(n  40) p Value
Target vessel 0.9
LAD 22 (55) 22 (55)
LCX 7 (18) 6 (15)
RCA 11 (27) 12 (30)
Lesion type B2/C 24 (60) 22 (55) 0.7
Stents, n 1.2 0.4 1.3 0.5 0.6
Stent diameter, mm 3.1 0.5 3.1 0.4 0.8
Total stent length, mm 24.0 12.8 23.6 12.1 0.9
Post-dilation 13 (33) 16 (40) 0.5
Maximum inﬂation pressure, atm 16.7 2.7 16.2 3.2 0.5
Use of drug-eluting stent 27 (68) 30 (75) 0.5
Direct stent 7 (18) 6 (15) 0.6
Peak activated clotting time, s 327 56 326 61 0.9
Values are n (%) or mean SD.
LAD  left anterior descending artery; LCX  left circumflex artery; RCA  right coronarybartery.[interquartile range (IQR): 8.8 to 18.0] vs. 17.6 [IQR:
9.7 to 33.9], p  0.007). There was no correlation
between IMR and FFR (r  0.05, p  0.7). For IMR
measurements, the correlation coefficient was 0.908
(mean difference: 6.1  7.4).
An increase of CK-MB above the upper normal limit
ccurs in 23% of patients in the pravastatin group versus
3% in the control group (p  0.3). Post-PCI elevations of
roponin I above the upper normal limit occurred in 58% of
atients in the pravastatin group versus 60% in the control
roup (p  0.8). However, troponin I elevation more than
 the upper limit of normal level tended to be less
ommon in the pravastatin group than in the control group
13% vs. 33%, p  0.06). Although post-PCI CK-MB and
roponin I values were significantly greater in patients with
ide branch occlusion than in those without side branch
cclusion (median: 17.0 [IQR: 16.8 to 33.8] vs. 11.0 [IQR:
.0 to 15.0], p  0.03; 0.36 [IQR: 0.25 to 2.56] vs. 0.13
IQR: 0.10 to 0.37], p  0.01), post-PCI IMR values were
imilar between them (median: 10.7 [IQR: 8.2 to 14.5] vs.
4.3 [IQR: 9.4 to 26.5], p  0.3). In patients with side
ranch occlusion, post-PCI cardiac markers were similar
Table 4. Angiographic and IVUS Analysis and
Physiological Measurements
Pravastatin
(n  40)
Control
(n  40) p Value
Angiographic data
Minimum lumen diameter, mm 1.1 0.4 1.0 0.5 0.7
Reference diameter, mm 2.8 0.4 2.8 0.5 0.9
Percent stenosis, % 61 13 64 12 0.5
IVUS data
Plaque morphology 0.7
Soft 7 (18%) 6 (15%)
Fibrous 12 (30%) 13 (33%)
Mixed 18 (45%) 15 (38%)
Calciﬁed 3 (8%) 6 (15%)
Minimum lumen area, mm2 2.6 1.1 2.3 1.4 0.3
Vessel area, mm2 9.5 3.9 9.3 3.5 0.5
Plaque area, mm2 6.9 4.1 7.0 3.2 0.7
Plaque burden, % 73 9 75 8 0.8
Remodeling index 1.02 0.21 0.99 0.18 0.6
Post-minimum stent area, mm2 6.1 3.2 5.9 3.8 0.4
Physiological data
FFR pre-PCI 0.68 0.16 0.70 0.11 0.5
FFR post-PCI 0.95 0.04 0.97 0.04 0.3
IMR post-PCI 14.9 9.0 26.7 25.2 0.007
Biomarkers
Post-PCI troponin I, ng/ml 0.34 0.60 0.59 0.76 0.1
CK-MB, U/l 14.1 9.9 16.4 13.0 0.4
Values are mean SD or n (%).
CK-MB  creatine kinase-myocardial band; FFR  fractional flow reserve; IMR  index of
microcirculatory resistance; IVUS intravascular ultrasound; PCI percutaneous coronary inter-
vention.etween patients in the pravastatin and control groups.
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517Mean post-PCI IMR values were significantly greater in
patients with troponin I elevation more than 5 the upper
limit of normal level (n  18) than in patients without
troponin I elevation more than 5 the upper limit of
normal level (n  62): 31.5 (IQR: 17.0 to 54.1) and 11.6
(IQR: 9.0 to 18.0), respectively (p  0.001). Distribution
pattern of IMR values both in the pravastatin group and the
control group according to post-PCI troponin I value was
shown in Figure 1. Some patients indicated low post-PCI
IMR value with troponin release (Fig. 2). In the whole
sample, we found a weak positive correlation between IMR
and pre-PCI C-reactive protein levels (r  0.28, p  0.01).
Predictors of microcirculation damage after PCI. As a point
f reference, in a study including patients with stable
oronary disease and no obvious microvascular dysfunction,
he mean IMR was 22 (14). There were 7 patients (18%)
ith IMR22 in the pravastatin group and 16 (40%) in the
ontrol group (p  0.03). Multivariate logistic regression
analysis was performed to determine the independent pre-
dictors of microcirculation damage after PCI. The fol-
lowing variables were tested (all with p  0.2 in univar-
iate analysis): pravastatin, stent size, maximum balloon
inflation pressure, diabetes mellitus, C-reactive protein
level, IVUS plaque burden, and creatinine level. The only
independent predictor of IMR 22 was absence of
pravastatin before PCI (p  0.03).
Discussion
The main finding of this study is that pravastatin therapy
before PCI is associated with preserved coronary artery phys-
iology after PCI at the level of the microvascular bed assessed
with IMR, an invasive wire-based quantitative measure of
Figure 1. Distribution of IMR Values Among Patients Treated With and
Without Pravastatin According to Post-PCI Troponin I Value
Solid circles show troponin I 5 the upper limit of normal level; open
circles show troponin I 5 the upper limit of normal level. IMR  indexw
of microcirculatory resistance; PCI  percutaneous coronary intervention.microvascular function. Our data suggest that pre-treatment
with statin is desired in patients undergoing elective PCI for
stable angina pectoris.
Asymptomatic myocardial damage, evaluated by post-
procedural cardiac markers elevation, has been shown to
occur frequently after otherwise successful PCI (4–8). It has
een reported that patients with cardiac marker increases
ad higher late mortality and more unfavorable event-free
urvival than did those patients with a normal cardiac
arker after PCI (9,10). It is generally considered that the
mechanism of cardiac marker release is distal embolization
of atherothrombotic material accompanying the plaque
disruption that is essential to the success of the PCI
procedure. Previous studies reported that thrombosis either
of a side branch occlusion or by distal embolization appears
to be a major culprit for cardiac marker release after PCI
(18–20). However, these different etiologies of cardiac
marker release after PCI cannot be differentiated by mea-
suring serum cardiac marker levels. The IMR has been used
in humans to assess the microcirculation in various clinical
settings, such as in acute myocardial infarction, (21), stable
ngina pectoris (16), and after cardiac transplantation (22).
n this study, the IMR was measured after coronary stent-
ng. Therefore, there was no angiographically residual signif-
cant stenosis present, which allowed the use of the simpler
quation for IMR. In this study, patients with pravastatin
reatment had significantly lower IMR value than did patients
ithout pravastatin treatment. Although the exact mechanism
s unclear, these observations suggest that pre-treatment with
ravastatin induces important changes in the plaque morphol-
gy, reducing inflammatory activity and favoring a reduction in
he relative content of cholesterol esters that are important
actors influencing plaque stability. Our results support the
ypothesis that statins stabilize atherosclerotic plaques and
educe distal embolization of plaque materials.
In several randomized trials (1–3), statin therapy was
enerally started after PCI; in addition, those trials were not
pecifically focused on the effect of statins on periprocedural
icrovascular damage. In the current study, patients were
tarted on pravastatin treatment 1 month before PCI regardless of
heir cholesterol levels. A previous randomized study (5) indicated
hat pre-treatment with atorvastatin 40 mg/day for 7 days
educed serum cardiac marker elevation after PCI. Prava-
tatin was used in the current study, because some studies
eported that the lipophilic statins would be expected to
enetrate cell membranes more effectively than the more
ydrophilic statins, causing more side effects (23). In line
ith the current study, a previous study (24) demonstrated
hat 2 weeks of treatment with pravastatin improved vascu-
ar abnormality through alteration in microcirculation without
ny episode of side effects. The correlation between the reduction
f low-density lipoprotein (LDL) cholesterol and the post-PCI
MR value was not significant in the current study (data
ere not shown). One of the reasons might be that patients
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518were started on pravastatin treatment 1 month before PCI
in the current study. The mechanisms underlying the
beneficial effects of pravastatin in reducing microvascular
damage after PCI are not completely clear. Pleiotropic
effects unrelated to LDL cholesterol reduction might be one
of the mechanisms underlying the prevention of microvas-
cular damage during PCI. Animal studies of cholesterol
reduction demonstrate changes in plaque structure includ-
ing reduction of macrophage numbers and matrix
metalloproteinase-1 expression and increases in interstitial
collagen content resulting in increased plaque stability (25).
Clinical studies of statin treatment, using IVUS, have
consistently demonstrated increases in hyperechogenicity
index (suggesting an increase in fibrous tissue), reductions in
the plaque lipid pool, but only modest reductions in plaque
volume (26). Another potential mechanism may be through
he anti-inflammatory properties of pravastatin. Chan et al.
27) reported that the anti-inflammatory effects of statins
lays a role, showing that the benefit was higher in patients
Figure 2. Measurement of Post-PCI IMR and Cardiac Markers
(A) Patient received pre-treatment of pravastatin (20 mg/day). Pre-PCI angiogr
post-PCI angiogram showed a good result without residual stenosis, side bran
patient exhibited post-PCI cardiac markers elevations (troponin I 1.25 ng/ml
ever, angiogram did not show evidence of epicardial coronary ﬂow disturbanc
FFR  fractional ﬂow reserve; Pa  arterial pressure; Pd  distal pressure; othith high C-reactive protein. This anti-inflammatory effectof statins might contribute to reduce microcirculation dam-
age due to microembolization during PCI. In the current
study, there was a linear relationship between post-PCI
IMR values and pre-PCI C-reactive protein levels.
The results of the current study support the previous
reports demonstrated that statin therapy is an independent
predictor of survival benefit after PCI (28). The advantage
f statins in coronary heart disease can be explained not only
y their lipid-lowering effect, but also by nonlipid-related
echanism, the “pleiotropic effects.” The pleiotropic effects
f statins are believed to include antiproliferative, anti-
nflammatory, and immunomodulatory actions; the property
o improve endothelial dysfunction; and increasing of nitric
xide bioavailability.
Study limitations. This study was a single-center study with
a relatively small study population. Further multicenter
studies are required to reconfirm the results in a larger
number of patients. Even though all patients were randomly
assigned to either pravastatin treatment or no treatment, a
monstrated a 90% stenosis in the mid right coronary artery. (B) Although
lusion occurred. (C) IMR  Pd mean  mean transit time hyperemia. The
reatine kinase-myocardial band  33 U/l) due to side branch occlusion. How-
IMR value was low. CFR  coronary ﬂow reserve; dT  delta temperature;
reviations as in Figure 1.am de
ch occ
and c
e andplacebo group was not included in this study. In the current
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519study, the 20-mg dose of pravastatin was used, because it is
the maximal approved dose in Japan. The 20-mg dose of
pravastatin seems to be less than the dose (40-mg dose of
atorvastatin) in trials in Western countries (5). Therefore,
our results may not be applicable to other ethnic groups, but
the degree of LDL cholesterol reduction (31%) by 20-mg
ose of pravastatin in this study was larger than that with
0-mg dose in the PROVE IT–TIMI 22 (Pravastatin or
torvastatin Evaluation and Infection Therapy–Thrombolysis
n Myocardial Infarction 22) trial (22%). Quantitative as-
essment of the plaque composition with radio frequency
nalysis of ultrasound backscatter signals was not performed in
he current study. The baseline IMR values were not calcu-
ated, because coronary wedge pressure before PCI was not
easured in this study. The duration of these microcircu-
atory damages is unknown; in fact, in the absence of cardiac
arker elevation, there may not be any damage. The
tatistical power was insufficient to find the correlation
etween the reduction of LDL cholesterol level and pre-
ention of microvascular damage during PCI. Finally, it is
till unknown whether impaired IMR can predict long-term
utcomes in patients with stable angina pectoris. Further
nvestigation is needed to clarify the association between
ost-procedure IMR impairment and adverse short- and
ong-term clinical outcomes.
onclusions
Post-PCI measurement of the IMR confirmed that pre-
treatment with pravastatin was associated with reduced
microvascular dysfunction induced by PCI regardless of side
branch occlusions. These data suggest that pre-treatment
with statins is desired in patients undergoing elective PCI
for stable angina pectoris.
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